Dave Maraldo, Ph.D., president of manufacturing at Merck, explains how flexible capacity, earlier input from manufacturing in R&D, and digital tools are helping the organization keep up with a faster, more varied portfolio.
|Articles|December 18, 2015
Isis Pharmaceuticals Changes Company Name
December 18, 2015.
Advertisement
Isis Pharmaceuticals (Arlsbad, CA) today announced that the company has changed its name to Ionis Pharmaceuticals (pronounced "eye-OH-nis") for obvious reasons.
Lynne Parshall, chief operating officer at Ionis, said: "We decided to change our company name because, when people see or hear our name, we want them to think about the life-saving medicines we are developing."
In conjunction with the corporate name change, the company will trade on the NASDAQ Global Select Market under the new ticker symbol "IONS". In addition, it has a new website address:
Advertisement
Related to this article
The Treasury Department is proposing rules to add biotechnology to its Outbound Investment Security Program under the COINS Act.
METiS TechBio enters a collaboration with Eli Lilly to develop next-generation, tissue-specific lipid nanoparticle delivery technologies using METiS’s AI-driven lipid discovery platform.
Advertisement
Advertisement
Trending on PharmExec
1
FDA Approves Subcutaneous Induction for Skyrizi in Crohn's Disease
2
FDA Approves Hibsago (Bepirovirsen) for Chronic Hepatitis B
3
Pharmaceutical Executive Daily: Treasury Issues Notice to Add Biotech into Proposed COINS Act
4
Treasury Proposes Rules Adding Biotechnology to Outbound Investment Security Program
5